CA2848724A1 - Inhibiteurs de phosphatidylinositol 3-kinase pour le traitement du cancer - Google Patents
Inhibiteurs de phosphatidylinositol 3-kinase pour le traitement du cancer Download PDFInfo
- Publication number
- CA2848724A1 CA2848724A1 CA2848724A CA2848724A CA2848724A1 CA 2848724 A1 CA2848724 A1 CA 2848724A1 CA 2848724 A CA2848724 A CA 2848724A CA 2848724 A CA2848724 A CA 2848724A CA 2848724 A1 CA2848724 A1 CA 2848724A1
- Authority
- CA
- Canada
- Prior art keywords
- nhc
- amino
- compound
- phenyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161534836P | 2011-09-14 | 2011-09-14 | |
US61/534,836 | 2011-09-14 | ||
US201161543529P | 2011-10-05 | 2011-10-05 | |
US61/543,529 | 2011-10-05 | ||
US201161562670P | 2011-11-22 | 2011-11-22 | |
US61/562,670 | 2011-11-22 | ||
PCT/US2012/055387 WO2013040337A1 (fr) | 2011-09-14 | 2012-09-14 | Inhibiteurs de phosphatidylinositol 3-kinase pour le traitement du cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2848724A1 true CA2848724A1 (fr) | 2013-03-21 |
Family
ID=46940622
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2848724A Abandoned CA2848724A1 (fr) | 2011-09-14 | 2012-09-14 | Inhibiteurs de phosphatidylinositol 3-kinase pour le traitement du cancer |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2755654A1 (fr) |
KR (1) | KR20140077911A (fr) |
AU (1) | AU2012308414A1 (fr) |
BR (1) | BR112014005858A2 (fr) |
CA (1) | CA2848724A1 (fr) |
IL (1) | IL231448A0 (fr) |
IN (1) | IN2014CN02671A (fr) |
TW (1) | TW201325592A (fr) |
UY (1) | UY34339A (fr) |
WO (1) | WO2013040337A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113754565B (zh) * | 2021-11-09 | 2022-02-22 | 南京威凯尔生物医药科技有限公司 | 一种连续流微反应器中制备沙库巴曲中间体的方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US7019002B2 (en) | 2001-12-11 | 2006-03-28 | Pharmacia & Upjohn, S.P.A. | Pyridopyrimidinones derivatives as telomerase inhibitors |
EP2322523B1 (fr) | 2005-10-07 | 2019-01-02 | Exelixis, Inc. | Procédé de préparation d'inhibiteurs de PI3Kalpha de type pyridopyrimidinone |
AU2006302179C1 (en) * | 2005-10-07 | 2013-06-20 | Exelixis, Inc. | N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
WO2007044481A1 (fr) | 2005-10-07 | 2007-04-19 | Basf Corporation | Composition de revetement d’enduit lustre |
EP2139483B9 (fr) * | 2007-04-11 | 2014-05-21 | Exelixis, Inc. | Therapies combinatoires comprenant un inhibiteur de pi3k-alpha de type quinaxoline pour leur utilisation dans le traitement du cancer |
WO2010146391A1 (fr) * | 2009-06-15 | 2010-12-23 | Generics [Uk] Limited | Synthèse régiosélective de létrozole |
WO2012065057A2 (fr) * | 2010-11-12 | 2012-05-18 | Exelixis, Inc. | Inhibiteurs de la phosphatidylinositol 3-kinase et leurs procédés d'utilisation |
-
2012
- 2012-09-14 CA CA2848724A patent/CA2848724A1/fr not_active Abandoned
- 2012-09-14 EP EP12766542.0A patent/EP2755654A1/fr not_active Withdrawn
- 2012-09-14 UY UY0001034339A patent/UY34339A/es not_active Application Discontinuation
- 2012-09-14 BR BR112014005858A patent/BR112014005858A2/pt not_active Application Discontinuation
- 2012-09-14 IN IN2671CHN2014 patent/IN2014CN02671A/en unknown
- 2012-09-14 WO PCT/US2012/055387 patent/WO2013040337A1/fr active Application Filing
- 2012-09-14 TW TW101133789A patent/TW201325592A/zh unknown
- 2012-09-14 AU AU2012308414A patent/AU2012308414A1/en not_active Abandoned
- 2012-09-14 KR KR1020147009539A patent/KR20140077911A/ko not_active Application Discontinuation
-
2014
- 2014-03-11 IL IL231448A patent/IL231448A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112014005858A2 (pt) | 2017-06-13 |
IN2014CN02671A (fr) | 2015-07-03 |
IL231448A0 (en) | 2014-04-30 |
WO2013040337A1 (fr) | 2013-03-21 |
KR20140077911A (ko) | 2014-06-24 |
TW201325592A (zh) | 2013-07-01 |
AU2012308414A1 (en) | 2014-05-01 |
UY34339A (es) | 2013-04-30 |
EP2755654A1 (fr) | 2014-07-23 |
WO2013040337A9 (fr) | 2014-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3601281B1 (fr) | Formes cristallines de l'acide 4-(1-(1,1-di(pyridin-2-yl)éthyl)-6-(3,5-diméthylisoxazol-4-yl)-1h- pyrrolo[3,2-b]pyridin-3-yl)benzoïque en tant que inhibiteur de bromodomaine | |
AU2008236562B2 (en) | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha | |
EP2142544B1 (fr) | Composés pyrido [2, 3-d]pyrimidin-7-one utilisés en tant qu'inhibiteurs de pi3k-alpha pour le traitement du cancer | |
TW201306842A (zh) | 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法 | |
CN105120868A (zh) | 组合治疗 | |
JP2010523677A (ja) | 癌の治療のためのPI3Kα阻害剤としてのピリド[2,3−D]ピリミジン−7−オン | |
KR20190058550A (ko) | 병용 요법 | |
WO2012149308A1 (fr) | Méthode de traitement d'un lymphome à l'aide d'inhibiteurs de pyridopyrimidinone de pi3k/mtor | |
CA2848724A1 (fr) | Inhibiteurs de phosphatidylinositol 3-kinase pour le traitement du cancer | |
WO2013056067A1 (fr) | Composés pour une utilisation dans le traitement de carcinome des cellules basales | |
MX2011009413A (es) | Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |
Effective date: 20150915 |